The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
Featured:
Vinod PullarkatDuring the EHA2021 Virtual Congress, the MDS Hub spoke with Vinod Pullarkat, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
Pullarkat discusses the hematoloigc toxicities associated with venetoclax and azacitidine, which are largely related to cytopenias. He explains that the key to managing these toxicities is close monitoring of patients and providing transfusion support as needed. Finally, he mentions that a high percentage of patients will require dose modifications.